Cramer reported that the top-performing marker was CA 125, followed by human epididymis protein 4 (HE4) and CA 72-4
29 (30%), CA 72-4 (27%), AFP (22%), and Cyfra 21-1 (9%).
Keywords: cancer, gastric cancer, stomach cancer, carcinoembryonic antigen, alpha-fetoprotein, CEA, AFP, CA 50, CA 19-9, CA 195, CA 72-4, CA 125, CA 15-3, CA 27.
CA 72-4 is the principal tumor antigen in current use for the diagnosis and prognosis of gastric cancer.
CA 72-4 is a 1 million kDa mucin-like glycoprotein complex (TAG 72) which is predominantly associated with human adenocarcinoma of the gastrointestinal tract (Johnson et al.
Clinical significance of the tumour markers CA 125 II and CA 72-4
in ovarian carcinoma.
CA 125 II, CA 19-9 and CYFRA 21-1 are trademarks and CA 15-3 and CA 72-4
are registered trademarks of Fujirebio Diagnostics, Inc.
Stomach cancers showed 84% detection with Serum-RECAF(TM), a value unattainable by any other current blood test such as CA 19-9(TM), which detects 56% of stomach cancers with only 75% specificity and CA 72-4
(TM) which has a 51% sensitivity with 97% specificity.
The five tumor markers are: CA 19-9 and CA 72-4
for gastrointestinal cancers, Prostate Specific Antigen (PSA) for prostate cancer, CA 15-3 for breast cancer, and CA 125 for ovarian cancer.
Beacon has gained the rights to five of Centocor's tumor markers: CA 19-9 and CA 72-4
for gastrointestinal cancers, especially of the pancreas and stomach, Prostate Specific Antigen (PSA) for prostate cancer, CA 15-3 for breast cancer, and CA 125 for ovarian cancer.
formerly Centocor Diagnostics) to market and sell their line of globally recognized "gold standard" tumor markers which include CA 125 II, CA 15-3, CA 19-9, CA 72-4
and CYFRA 21-1.
According to this agreement, Pasteur Sanofi Diagnostics will distribute on its Access automated instrument a range of five tumor markers developed by Centocor, including CA 19-9, CA 125, CA 15-3, CA 72-4
, and PSA.